The researchers initially used untargeted metabolomics to identify metabolites altered by cold in adult worms maintained at 15 °C, 20 °C or 25 °C. Two independent metabolomic experiments identified a shared set of cold-induced metabolites, among them BH2. Follow-up experiments connected this metabolic response to the enzyme CAT-4, the worm counterpart of human GCH1, which participates in biopterin synthesis. Increasing CAT-4 activity raised BH2 levels, and experimentally elevating CAT-4 in muscle was sufficient to reproduce several effects of cold even when animals remained at normal or elevated temperatures.

The tissue-specific experiments indicate that muscle acts as a metabolic hub in this response. BH2 produced in muscle was detected in distal tissues, including the intestine and neurons, where the salvage enzyme DHFR-1 converts it into BH4. Blocking the relevant steps weakened the cold-associated phenotypes, while restoring activity in selected tissues helped re-establish them. The results therefore support a metabolite-signalling model: a relatively mobile metabolic precursor made in one organ can be transported elsewhere and converted into a functional cofactor in tissues that need it.

BH4 has an important downstream role in the worm pathway. It serves as an essential cofactor for phenylalanine hydroxylase, PAH-1, which supports tyrosine synthesis. The investigators found that the lifespan effect of the BH2–BH4 pathway required this connection, and that supplementing worms with tyrosine reproduced the longevity benefit at normal temperature. These results identify the PAH-1–tyrosine axis as a downstream mediator rather than treating BH2 itself as the endpoint. They also show that the network can influence lifespan without a continuing fall in ambient temperature, provided its metabolic components are engaged.

The pathway had consequences beyond lifespan. Elevated BH2 synthesis in muscle reduced disease-related protein aggregation in distant tissues and preserved neuronal and intestinal function during ageing. Analyses of ageing worms showed less accumulation of aggregation-prone proteins, and tissue-specific perturbations indicated that the proteostatic effect depended on communication between muscle and recipient tissues. Tyrosine again mimicked part of this effect. In the study’s broader interpretation, the BH2–BH4 pathway therefore coordinates longevity and proteostasis rather than operating as an isolated response within individual cells.

Human-cell experiments provided a limited test of whether the pathway’s biochemical logic might be conserved in mammals. Researchers treated human cells with BH2 or tyrosine and measured aggregation of polyglutamine-expanded protein associated with Huntington’s disease, as well as disease-linked variants of TDP-43 and FUS associated with amyotrophic lateral sclerosis. Both BH2 and tyrosine reduced aggregation in the tested cellular models. Additional experiments involving human induced pluripotent stem-cell-derived motor neurons bearing a mutant FUS allele examined effects on cell death and necroptosis-related markers.

These cellular findings do not demonstrate that BH2 or tyrosine prevents neurodegeneration in people. The experiments involved cultured cells rather than patients, and translation may depend on whether and how BH2 is converted into BH4 in a particular mammalian tissue. The authors noted that BH4 is also required by nitric oxide synthase, and that oxidative stress or impaired DHFR activity can disturb the balance between BH2 and BH4 in endothelial cells. Although BH2 did not increase detectable superoxide production in the cellular models used, those experiments did not directly test nitric oxide synthase uncoupling in living animals.

The study also identified a biochemical limitation to the proposed mechanism. Oxidative stress reduced BH2’s protective effect, consistent with interference in the conversion of BH2 to BH4, whereas tyrosine retained its protective effect under those conditions. This difference suggests that the downstream amino-acid pathway can remain effective even when efficient BH2-to-BH4 conversion is compromised. The result is a mechanistic distinction between the cold-induced upstream signal, BH2, and the downstream effector, tyrosine. It also shows why directly supplementing BH2 may not reproduce all of the pathway’s effects in every biological context.

The work was conducted primarily in adult hermaphrodite worms, with synchronized populations, randomized allocation to experimental conditions and lifespan assays generally using 96 animals per condition. Experiments were repeated by at least two researchers, although sample sizes were not determined through statistical power calculations and conditions were not processed in a blinded manner. Metabolomic samples were randomized during processing, while proteomic analysis and molecular assays examined changes across cold temperatures and tyrosine treatment. The worm results therefore establish a causal pathway within the experimental model, but their relevance to mammalian aging, disease prevention and human supplementation remains untested.

Cold also induced numerous metabolites beyond BH2, indicating that the newly identified pathway is likely part of a broader network of temperature-responsive signals. Future work would need to determine how these metabolites interact, whether similar tissue-to-tissue transport occurs in mammals, and whether BH2 delivery can reproduce cold-associated benefits without requiring changes in body temperature. For now, the study offers a detailed molecular account of how moderate cooling in worms can coordinate lifespan and protein quality control: muscle increases production of a transportable BH2 reservoir, distant tissues convert it into BH4, and a PAH-1-dependent tyrosine pathway helps translate that metabolic signal into longer life and reduced protein aggregation.

Subject of Research: Cold-induced BH2 metabolism, intertissue signalling, longevity and proteostasis in nematodes

Article Title: Cold activates a BH2 metabolic network promoting longevity and proteostasis

Article References: Lee, H. J., Doğan, C., Koyuncu, S., Wehrmann, M., Artan, M., Petrovic, D., Loureiro, R., Sahu, A. K., Schnubel, J., Grobushkin, P., Prymidis, D., Georgomanolis, T., Sokol, A., Yang, M., Hoppe, T., Frezza, C., & Vilchez, D. (2026). Cold activates a BH2 metabolic network promoting longevity and proteostasis. Nature. https://doi.org/10.1038/s41586-026-11152-9

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11152-9

Keywords: BH2 metabolism, cold exposure, longevity, proteostasis, Caenorhabditis elegans, BH4, tyrosine, muscle signalling, protein aggregation, human cells, Cold, activates

Site-specific recombinases are enzymes that recognize short, defined DNA sequences and catalyze the exchange or insertion of genetic material between them. Tools such as Cre-lox, Flp-FRT, and Bxb1 have long been used to stitch donor DNA into a matching genomic location, offering an attractive alternative to random integration, which can disrupt genes or trigger unpredictable expression. Yet the practical utility of these systems has been hampered by a persistent problem: native attachment sites in complex genomes are often refractory to efficient recombination, and the pseudosites that recombinases occasionally recognize elsewhere in the genome tend to support only low levels of integration.

The new work tackles this limitation head-on by engineering the genomic attachment sites themselves. Rather than accepting whatever recombination sequences happen to exist at a chosen locus, the team designed optimized attachment sites whose sequence, spacing, and chromosomal context were tuned to maximize recombinase activity. These synthetic landing pads act as high-affinity docking stations: once installed at a specific chromosomal address, they allow a matching recombinase to insert incoming donor DNA with high fidelity and at efficiencies that make the technique practical for routine laboratory use.

A central challenge in building such landing pads is that recombination efficiency depends not only on the attachment sequence itself but also on the local chromatin environment. DNA packaged tightly into nucleosomes is less accessible to recombinases, and sites embedded in transcriptionally silent regions often perform poorly. The researchers therefore combined sequence optimization with careful selection of genomic contexts, identifying chromosomal positions in both plant and human cells where engineered attachment sites could function at peak efficiency. The resulting landing pads supported robust integration even when the surrounding chromatin was not particularly permissive, suggesting that the engineered sites themselves contribute substantially to recombinase access and activity.

In plant systems, the advance carries particular weight. Plants are notoriously difficult targets for precise genome editing because delivered DNA most often integrates at random positions through the cell’s own repair machinery, producing lines with variable transgene expression and unpredictable agronomic traits. Engineered attachment sites now offer a way to direct transgenes repeatedly to the same, pre-validated locus. For crop development, this means that a trait conferring disease resistance or drought tolerance could be introduced into an identical genomic address across breeding lines, ensuring consistent expression and simplifying regulatory assessment of insertion effects.

The parallel demonstration in human cells underscores the platform’s generality. In mammalian biotechnology, targeted integration is essential for producing cell lines that manufacture therapeutic proteins, for engineering immune cells with defined genetic payloads, and increasingly for experimental gene therapy approaches where a transgene must land at a single, safe harbor location. The engineered sites enabled high-efficiency integration using recombinase systems that had previously delivered only modest yields, reducing the screening burden typically required to isolate correctly modified clones. This improvement translates directly into time and cost savings for laboratories and biomanufacturing facilities that depend on reproducible genetic constructs.

Technically, the study involved iterative design and testing of attachment site variants, evaluating how changes in the core recognition sequence and flanking regions affected recombination rates. The researchers systematically compared candidate sites, measuring the proportion of cells in which donor DNA was inserted at the intended location and assessing the stability of the resulting integrations over successive cell divisions. The best-performing engineered sites supported integration efficiencies that were markedly higher than those observed at unmodified genomic pseudosites, and molecular characterization confirmed that the inserted cargo remained intact and correctly oriented, with no evidence of the rearrangements that often complicate random integration approaches.

The work also highlights an important conceptual shift in genome engineering. Much of the field’s attention in recent years has focused on improving the enzymes themselves—engineering recombinases, CRISPR-associated proteins, and other genome editors with altered specificities. This study demonstrates that the genomic target can be just as powerful a variable. By treating the landing site as an engineered component rather than a fixed constraint, researchers gain an additional layer of control over integration outcomes. The strategy is complementary to enzyme engineering: an optimized enzyme working at an optimized site delivers results neither could achieve alone.

Looking ahead, the platform could reshape how synthetic biology constructs are deployed in living systems. Stable, single-copy integration at defined loci is a prerequisite for predictable expression of multi-gene pathways, biosynthetic circuits, and therapeutic payloads. Engineered attachment sites provide a standardized interface between delivered DNA and the genome, much as standardized parts underpin circuit design in electronics. As libraries of validated landing pads and matching recombinases accumulate, researchers envision modular workflows in which any genetic construct can be directed into any of a panel of pre-characterized genomic addresses, in plants or in human cells, with efficiencies that no longer limit experimental design.

The implications extend to safety and regulatory considerations as well. Integration at a single, well-characterized site minimizes the risk of insertional mutagenesis and position effects, two of the chief concerns surrounding genetically modified organisms and cell therapies. By making targeted integration both efficient and routine, engineered landing pads move the field closer to genome engineering that is not only powerful but also predictable—a property that regulators, clinicians, and agricultural scientists have long demanded. As the technology matures, its adoption across crop improvement, biomanufacturing, and cell-based medicine seems likely to accelerate, marking a significant step forward in the quest to write genetic information into genomes with confidence and control.

Subject of Research: Engineering genomic attachment sites for site-specific recombinases to enable high-efficiency targeted DNA integration in plants and human cells

Article Title: Engineered genomic attachment sites for site-specific recombinases enable high-efficiency integration in plants and human cells

Article References: Yan, L., Zhou, L., Gao, Q., Li, L., Guo, L., Ran, Y., Zhang, L., Zhang, K., Wang, Z., Li, Y., Li, S., & Zhao, K. T. (2026). Engineered genomic attachment sites for site-specific recombinases enable high-efficiency integration in plants and human cells. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03294-y

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03294-y

Keywords: site-specific recombinases, genomic landing pads, targeted gene integration, genome engineering, plant biotechnology, human cells, attachment sites, transgene insertion, safe harbor loci, synthetic biology, chromatin accessibility, Nature Biotechnology